Mendus has enroled the first 10 patients in the phase Ib VITAL-CML study. Although small, the imminent planned interim safety readout from 8 patients is crucial in enabling the follow-on trial in TFR. In addition to safety, molecular measurements of disease will follow. Consistent early detectable changes in molecular response levels (MR) would de-risk the entire CML programme and be a major catalyst. The DIVA study combining vididencel with venetoclax + azacitidine in AML should start anytime with readouts in 2027, while we expect data from the first 20 CADENCE patients over the next months. A new pediatric AML study is being investigated. It would enable an extremely cost-efficient and quick way to the US market. The Mendus share screens as "cheap".
LÄS MER
